Artemis Medical Inc.
This article was originally published in Start Up
Artemis Medical hopes to combine the diagnostic accuracy of surgical biopsy with the comfort and rapid healing time of minimally invasive biopsy, with a device that can remove an architecturally intact 12mmX 14mm sample of tissue through a 6mm skin opening.
You may also be interested in...
In breast cancer, the need for less invasive alternatives to surgery is gaping, particularly on the diagnostic side. Following routine screening mammography, 1.4 million women in the US each year have breast biopsies once a radiologist identifies a suspicious lesion. However, only 20% of women undergoing biopsies will be found to have cancer and not just abnormal, but benign growths. Several new companies have gone to the drawing board to remedy the shortcomings of biopsy devices.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.